Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.552 USD | -7.20% | +13.42% | -62.11% |
Financials (USD)
Sales 2024 * | 25.22M | Sales 2025 * | 32.65M | Capitalization | 3.78M |
---|---|---|---|---|---|
Net income 2024 * | -24M | Net income 2025 * | -9M | EV / Sales 2024 * | 0.15 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.12 x |
P/E ratio 2024 * |
-0.16
x | P/E ratio 2025 * |
-0.71
x | Employees | 25 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.23% |
Latest transcript on Eiger BioPharmaceuticals, Inc.
1 day | -7.20% | ||
1 week | +13.42% | ||
Current month | +18.70% | ||
1 month | +13.42% | ||
3 months | -55.46% | ||
6 months | -76.11% | ||
Current year | -62.11% |
Managers | Title | Age | Since |
---|---|---|---|
David Apelian
CEO | Chief Executive Officer | 59 | 17-06-13 |
James Vollins
CMP | Compliance Officer | 55 | 23-04-12 |
Colin Hislop
CTO | Chief Tech/Sci/R&D Officer | 66 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 57 | 22-07-17 | |
Thomas Dietz
CHM | Chairman | 60 | 16-03-21 |
David Apelian
CEO | Chief Executive Officer | 59 | 17-06-13 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.03% | 0 M€ | 0.00% | - | |
0.00% | 17 M€ | +5.25% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 2.552 | -7.20% | 307 |
24-05-16 | 2.75 | +22.22% | 3,846 |
24-05-15 | 2.25 | +6.13% | 2,240 |
24-05-14 | 2.12 | -5.78% | 404 |
24-05-13 | 2.25 | -0.99% | 15,120 |
Delayed Quote OTC Markets, May 17, 2024 at 02:21 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-62.11% | 4.07M | |
+33.63% | 50.85B | |
-0.09% | 42.82B | |
+49.62% | 42.03B | |
-4.96% | 29.55B | |
+11.18% | 26.11B | |
-21.95% | 19.13B | |
+8.61% | 13.05B | |
+28.31% | 12.16B | |
+24.73% | 12.08B |
- Stock Market
- Equities
- EIGR Stock